Athersys

Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Athersys, Inc. is a biotechnology company, which focuses on the field of regenerative medicine. It engages in the discovery and development of therapies designed to extend and enhance the quality of human life. The firm offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.

Athersys' (ATHX) CEO Gil Van Bokkelen on Q4 2019 Results - Earnings Call Transcript

Athersys And The Law Of Large Numbers

Athersys & The Law Of Large Numbers

Highly experienced pharmaceutical industry executive joins leadership team as Company begins planning for potential approval and commercialization of MultiStem® Highly experienced pharmaceutical industry executive joins leadership team as Company begins planning for potential approval and commercialization of MultiStem®

Athersys Names Ivor Macleod Chief Financial Officer

One-year results support positive 28-day findings and suggest further benefits for ARDS patients One-year results support positive 28-day findings and suggest further benefits for ARDS patients

Athersys Provides Update on One-Year ARDS Study Data

Designation will expedite review for HLCM051 (MultiStem® Cell Therapy) for ARDS program in Japan Designation will expedite review for HLCM051 (MultiStem® Cell Therapy) for ARDS program in Japan

Healios Receives Notification of Orphan Designation  for Acute Respiratory Distress Syndrome Clinical Program

Athersys, Inc. (ATHX) CEO Gil Van Bokkelen on Q3 2019 Results - Earnings Call Transcript

Conference being held October 2nd- 4th, 2019 in Carlsbad; live video webcast available Conference being held October 2nd- 4th, 2019 in Carlsbad; live video webcast available

Athersys to Present at 2019 Cell & Gene Meeting on the Mesa

We review significant developments in the last three months in our the stem cell triple play and how they create value moving forward.

The Stem Cell Triple Play Revisited

I will give a quick overview of Athersys and their MultiStem product.

Athersys: Potential Upside

Athersys, Inc. (ATHX) on Q2 2019 Results - Earnings Call Transcript

Cytori Therapeutics

Understanding the basics of the stem cell sector.

The Stem Cell Triple Play: 3 Companies WIth Great Value Drivers

Biogen

Hypoxia is a core problem in stroke and other ischemic injuries.

Time Is Brain: Bioxytran's Tissue Oxygenation Therapy May Breathe New Life Into Stroke Victims

The FDA has given the company's lead drug platform a potential leg up in development.

Here's Why Athersys Rose as Much as 15.2% Today

ATHX is developing a stem cell therapy that enlarges the window of treatment for ischemic strokes.

Athersys: Stem Cell Therapy For Ischemic Stroke

Athersys, Inc. (ATHX) Q1 2019 Results - Earnings Call Transcript

The stem cell pioneer announced an update with its most important collaborator.

Here's Why Athersys Is Soaring Today

Athersys (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Athersys (ATHX) Upgraded to Strong Buy: Here's What You Should Know

Athersys may be first to fully tap the gigantic ischemic stroke market.

Athersys Is Poised To Snatch The Holy Grail Of Acute Injury

Athersys, Inc. (ATHX) CEO Gil Van Bokkelen on Q4 2018 Results - Earnings Call Transcript

News for Athersys Stock (ATHX)